{"gene":"ELK4","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":2015,"finding":"CDK2 directly phosphorylates ELK4 at Thr194 and Ser387, and this phosphorylation regulates ELK4 transcriptional activity to control c-fos expression downstream of EGF signaling.","method":"In vitro kinase assay (CDK2 phosphorylates ELK4), site-directed mutagenesis at Thr194 and Ser387, transcriptional activity assays, knockdown of CDK2/ELK4 with phenotypic readout (EGF-induced cell transformation)","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation assay with specific residue identification, mutagenesis, and functional transcriptional readout; single lab but multiple orthogonal methods","pmids":["26028036"],"is_preprint":false},{"year":2020,"finding":"ELK4 is acetylated at K125; this acetylation enhances its interaction with BRD2, and the ELK4-BRD2 complex cooperatively binds ETS motifs in the LAMB3 promoter to drive LAMB3 transcription in colorectal cancer. The BET inhibitor JQ1 disrupts the ELK4-BRD2 interaction, reducing BRD2 occupancy at the LAMB3 promoter.","method":"ChIP, Co-IP, luciferase reporter assay, acetylation mapping at K125, JQ1/U0126 treatment with mRNA level readout","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — acetylation site identified, complex validated by Co-IP, promoter binding confirmed by ChIP, functional disruption by inhibitor; single lab with multiple orthogonal methods","pmids":["32398865"],"is_preprint":false},{"year":2014,"finding":"ELK4 co-regulates a distinct set of SRF-dependent genes related to external stimulus/infection responses in macrophages (separate from MKL1/2-regulated cytoskeletal genes), acting directly in cis at target gene promoters.","method":"Knockdown combined with gene expression array; ChIP-seq for genome-wide occupancy mapping","journal":"BMC genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq genome-wide occupancy plus knockdown/expression array; single lab, two orthogonal methods","pmids":["24758171"],"is_preprint":false},{"year":2011,"finding":"ELK4 binds to a functional ETS binding site in the Mcl-1 promoter and is a critical transcriptional regulator of Mcl-1 expression in glioma; ELK4 downregulation reduces Mcl-1 levels, increases apoptosis sensitivity, and reduces tumor formation in vivo. A SNP that ablates ELK4 binding correlates with lower Mcl-1 levels.","method":"Promoter analysis, ETS binding site identification, ELK4 knockdown with Mcl-1 mRNA/protein readout, glioblastoma xenograft model","journal":"Neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter binding assay, knockdown with defined molecular and in vivo phenotype; single lab, multiple methods","pmids":["21846680"],"is_preprint":false},{"year":2023,"finding":"PYCR1 is phosphorylated by nuclear IGF1R at Tyrosine 135 under hypoxia, and this phosphorylation promotes PYCR1 binding to ELK4 and recruitment of PYCR1 to ELK4-targeted gene promoters. PYCR1 enzymatic activity produces NAD+ that stimulates SIRT7 deacetylation of H3K18ac, cooperating with the ELK4-SIRT7 complex to mediate transcriptional repression.","method":"Phosphorylation mapping (Tyr135), co-IP for PYCR1-ELK4 interaction, ChIP for promoter recruitment, enzymatic activity assay for PYCR1-derived NAD+, SIRT7 deacetylation assay, in vivo xenograft","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — phosphorylation site mapped, protein-protein interaction validated by Co-IP, ChIP for promoter recruitment, enzymatic activity linked to deacetylation; single lab with multiple rigorous orthogonal methods","pmids":["37777542"],"is_preprint":false},{"year":2023,"finding":"ELK4 cooperates with SP1 and SP3 (rather than SRF) as functional partners at the genome-wide level in colorectal cancer; MAPK-induced phosphorylation of ELK4 facilitates its interaction with SP1/SP3. The ELK4-SP1/SP3 complex directly activates transcription of LRG1, a neoangiogenic factor.","method":"Integrated genomics and proteomics, ChIP-seq for genome-wide occupancy, Co-IP for ELK4-SP1/SP3 interaction, phosphorylation assay (serum-induced MAPK), luciferase reporter for LRG1 promoter, combination treatment with MEK inhibitor and mithramycin A","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP-seq, proteomics, Co-IP, phosphorylation, functional reporter assay, in vivo experiments; single lab with multiple orthogonal methods","pmids":["37786278"],"is_preprint":false},{"year":2021,"finding":"ELK4 transcriptionally activates KDM5A by directly binding its promoter; KDM5A then removes H3K4me3 from the PJA2 promoter to repress PJA2 expression, leading to reduced ubiquitination-mediated degradation of KSR1. This ELK4-KDM5A-PJA2-KSR1 axis promotes M2 macrophage polarization and gastric cancer progression.","method":"Dual luciferase reporter, ChIP, Co-IP, cycloheximide chase (KSR1 protein stability), gain/loss-of-function, xenograft model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase confirm direct promoter binding, Co-IP, protein stability assay; single lab, multiple orthogonal methods","pmids":["34372882"],"is_preprint":false},{"year":2021,"finding":"ELK4 transcription factor binds to the SNHG22 promoter and promotes SNHG22 lncRNA expression in gastric cancer cells.","method":"ChIP assay, luciferase reporter assay","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and luciferase confirm direct promoter binding; single lab, limited to promoter binding assay","pmids":["34663788"],"is_preprint":false},{"year":2018,"finding":"ELK4 (SAP-1) and ELK1 act cell-autonomously in the thymus downstream of ERK signaling to control the generation of innate-like αβ CD8+ T cells; mice lacking both ELK4 and ELK1 develop increased numbers of innate-like CD8+ T cells associated with reduced TCR-mediated activation of ELK4-SRF target genes (e.g., EGR2), and overexpression of EGR2 partially suppresses this phenotype.","method":"Elk4 and Elk1 knockout mice (genetic epistasis), thymic cell-autonomy demonstrated by bone marrow chimeras, target gene expression analysis, EGR2 overexpression rescue","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis using double KO mice, cell-autonomous rescue experiments, target gene analysis; single lab but multiple rigorous genetic methods","pmids":["30068599"],"is_preprint":false},{"year":2009,"finding":"The SLC45A3-ELK4 chimeric transcript is androgen-regulated (not wild-type ELK4), and is generated through a mechanism other than chromosomal rearrangement, most likely trans-splicing, in prostate cancer. SLC45A3 exon 1 is fused to ELK4 exon 2 in the major variant.","method":"RT-PCR characterization, quantitative PCR on DNA and RNA, androgen (R1881) treatment of LNCaP cells, FISH for chromosomal rearrangement","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (RT-PCR, qPCR, FISH, androgen treatment) in single study; cis-splicing mechanism later supported by independent lab (PMID 22787087)","pmids":["19293179"],"is_preprint":false},{"year":2017,"finding":"The SLC45A3-ELK4 fusion transcript functions as a long non-coding chimeric RNA (lnccRNA) to promote prostate cancer cell proliferation; the fusion RNA encodes the same protein as ELK4 but is present at <1% of wild-type ELK4 levels. A translation-incompetent mutant of the fusion RNA retains the ability to regulate cell proliferation and suppress CDKN1A, and the fusion RNA is enriched in the nuclear fraction.","method":"RNA silencing (selective knockdown of fusion vs. wild-type ELK4), rescue with translation-competent and translation-incompetent mutants, subcellular fractionation, cell proliferation assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — selective silencing, multiple rescue constructs, fractionation; single lab, multiple orthogonal approaches","pmids":["28716526"],"is_preprint":false},{"year":2023,"finding":"ELK4 binds to the FBXO22 promoter and transcriptionally inhibits FBXO22 expression, leading to reduced PTEN levels and promotion of cell cycle progression and stem cell-like characteristics in HPV+ cervical cancer cells.","method":"ChIP-qPCR, luciferase reporter assay, ELK4 knockdown with cell cycle and stemness phenotype readouts","journal":"Balkan medical journal","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and luciferase confirm binding, but single lab, limited mechanistic follow-up for PTEN regulation","pmids":["37519006"],"is_preprint":false},{"year":2023,"finding":"ELK4 positively modulates cytokine/chemokine (Hdc, Ccl3, Ccl4) transcription by interacting with MITF, while negatively regulating degranulation-related gene transcription by complexing with SIRT6 in mast cells. ELK4 knockout suppresses mast cell proliferation and impedes cell cycle progression.","method":"Elk4 knockout in BMMCs, gene expression analysis, Co-IP for ELK4-MITF and ELK4-SIRT6 interactions, transcriptional activity assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined cellular phenotypes, Co-IP for two distinct complexes; single lab, multiple orthogonal methods","pmids":["37529050"],"is_preprint":false},{"year":2024,"finding":"ELK4 directly binds to the CHMP6 promoter to transcriptionally activate CHMP6 expression, thereby inhibiting ferroptosis (reducing ROS and Fe2+ levels, increasing GPX4 and xCT, decreasing ACSL4) and promoting proliferation, invasion, and migration in skin cutaneous melanoma cells.","method":"ChIP assay for ELK4 binding to CHMP6 promoter, ELK4/CHMP6 overexpression and knockdown with ROS/Fe2+ measurements and ferroptosis marker protein levels","journal":"Archives of dermatological research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP confirms promoter binding, functional rescue data; single lab, limited mechanistic depth","pmids":["39305302"],"is_preprint":false},{"year":2025,"finding":"ELK4 acts as a transcription factor that directly binds the MSI2 promoter to promote MSI2 transcription in NSCLC, and MSI2 in turn promotes NSCLC progression through the TGF-β/SMAD3 pathway.","method":"ChIP assay, dual luciferase reporter assay, ELK4/MSI2 knockdown/overexpression with proliferation/invasion assays, xenograft model","journal":"The Kaohsiung journal of medical sciences","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and luciferase confirm direct binding; single lab, pathway placement by knockdown without reconstitution","pmids":["39969091"],"is_preprint":false},{"year":2024,"finding":"ELK4 promotes FNDC5 transcription by binding to the FNDC5 promoter; ELK4 overexpression in microglia suppresses neuroinflammation and cognitive dysfunction in an OSA mouse model through this FNDC5-dependent mechanism.","method":"Promoter binding assay (ChIP implied), ELK4 overexpression/FNDC5 knockdown rescue experiments in BV2 cells and OSA mouse model","journal":"Brain research bulletin","confidence":"Low","confidence_rationale":"Tier 3 / Weak — promoter binding assay and genetic rescue establish pathway placement; single lab, abstract-level detail only","pmids":["39173777"],"is_preprint":false},{"year":2025,"finding":"ELK4 transcriptionally upregulates METTL3 by direct promoter binding; METTL3 then stabilizes CEMIP mRNA, and the resulting ELK4-METTL3-CEMIP axis promotes stemness and malignant phenotypes in colorectal cancer.","method":"ChIP assay for ELK4 binding to METTL3 promoter, luciferase reporter, RIP and mRNA stability assay for METTL3-CEMIP, ELK4 knockdown xenograft","journal":"Journal of gastroenterology and hepatology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and luciferase confirm promoter binding; single lab, abstract-level detail for downstream axis","pmids":["40518958"],"is_preprint":false},{"year":2025,"finding":"ELK4 directly binds to DHFR enhancer regions to activate DHFR transcription, promoting vasculogenic mimicry and invasion in oral squamous cell carcinoma; DHFR overexpression rescues VM and invasion impairment caused by ELK4 knockdown.","method":"ChIP-qPCR for ELK4 binding to DHFR enhancer, ELK4 knockdown and DHFR rescue with Matrigel tube formation and Transwell invasion assays","journal":"Oncology research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP-qPCR confirms enhancer binding, functional rescue confirms pathway; single lab, limited mechanistic depth","pmids":["41502523"],"is_preprint":false},{"year":2025,"finding":"ELK4 binds to the HOMER3 promoter to promote its transcription in glioma; ELK4-driven HOMER3 expression activates the Wnt/β-catenin/EMT signaling pathway, promoting glioma cell proliferation and metastasis.","method":"ChIP for ELK4-HOMER3 promoter binding, HOMER3 silencing with proliferation/metastasis assays in vitro and in vivo, EMT marker expression","journal":"Biology direct","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP confirms promoter binding, functional data; single lab, abstract-level mechanistic detail","pmids":["40205485"],"is_preprint":false},{"year":2020,"finding":"LINC00662 mediates degradation of ELK4 mRNA through the Staufen-mediated mRNA decay (SMD) pathway in microvascular endothelial cells; reduced ELK4 increases BBB permeability by increasing tight junction-related protein expression.","method":"RNA knockdown, mRNA stability assay, BBB permeability assay, tight junction protein expression","journal":"RNA biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional pathway established by knockdown; single lab, SMD mechanism asserted but not fully reconstituted in abstract","pmids":["32372707"],"is_preprint":false},{"year":2022,"finding":"ELK4 transcription factor promotes SNHG22 lncRNA expression in gastric cancer; this was confirmed by ChIP and the 3' UTR of ELK4 mRNA is targeted by miR-92b-3p delivered by exosomes from mechanically unloaded MVECs, leading to suppressed osteogenic differentiation.","method":"ChIP (ELK4-SNHG22 promoter); luciferase reporter for miR-92b-3p targeting ELK4 3'UTR; siRNA-ELK4 rescue experiments","journal":"Journal of personalized medicine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — luciferase confirms 3'UTR targeting, siRNA rescue; single lab, functional context is indirect (exosome-mediated)","pmids":["36556251"],"is_preprint":false},{"year":2024,"finding":"ELK4 directly activates PD-L1 transcription in colorectal cancer; the lncRNA SNHG16 acts as a competitive endogenous RNA to sponge miR-324-3p, which normally suppresses ELK4 expression, thereby increasing ELK4-driven PD-L1 transcription and promoting immune escape.","method":"Dual luciferase assay, RIP, ChIP, knockdown/overexpression with immune escape functional assays (LDH cytotoxicity, flow cytometry)","journal":"Biochemical genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and luciferase confirm ELK4-PD-L1 promoter binding; single lab, pathway placement by knockdown","pmids":["39688781"],"is_preprint":false}],"current_model":"ELK4 is an ETS-family transcription factor (TCF subfamily) that acts primarily as a downstream effector of MAPK/ERK signaling: ERK-mediated phosphorylation (and CDK2 phosphorylation at Thr194/Ser387) enhances ELK4 transcriptional activity; ELK4 can form complexes with SRF (activating immediate-early genes such as c-fos and EGR family members in T cell development and stimulus responses), with BRD2 (dependent on ELK4 acetylation at K125, driving LAMB3 transcription in CRC), with SP1/SP3 in an SRF-independent manner (driving LRG1 in CRC), with MITF or SIRT6 in mast cells, and with PYCR1-SIRT7 to mediate H3K18ac deacetylation and transcriptional repression under hypoxia; ELK4 directly activates or represses multiple target gene promoters (Mcl-1, KDM5A, SNHG22, PD-L1, MSI2, METTL3, DHFR, HOMER3, CHMP6, FBXO22, FNDC5) and its own expression is post-transcriptionally regulated by miR-92b-3p (3'UTR targeting) and lncRNA-mediated mRNA decay."},"narrative":{"mechanistic_narrative":"ELK4 is a sequence-specific ETS-family transcription factor that functions as a downstream nuclear effector of MAPK/ERK signaling, binding ETS motifs at target promoters and enhancers to activate or repress transcription [PMID:37786278, PMID:21846680]. Its activity is gated by post-translational modification: CDK2 directly phosphorylates ELK4 at Thr194 and Ser387 to control c-fos expression downstream of EGF signaling [PMID:26028036], and MAPK-induced phosphorylation promotes its assembly with partner factors [PMID:37786278]. ELK4 operates through a versatile set of cofactor complexes whose composition dictates target specificity—it co-regulates SRF-dependent stimulus/infection-response genes [PMID:24758171], cooperates with SP1/SP3 in an SRF-independent manner to activate the neoangiogenic factor LRG1 [PMID:37786278], and depends on K125 acetylation to recruit BRD2 to the LAMB3 promoter [PMID:32398865]. Beyond classical activation, ELK4 mediates transcriptional repression: under hypoxia, phosphorylated PYCR1 binds ELK4 and is recruited to ELK4-target promoters, where PYCR1-derived NAD+ stimulates SIRT7-dependent H3K18ac deacetylation [PMID:37777542]. In immune and developmental contexts, ELK4 acts cell-autonomously in the thymus together with ELK1 to drive ERK-dependent SRF target genes such as EGR2 and restrain innate-like CD8+ T cell generation [PMID:30068599], and in mast cells it partitions between MITF (cytokine/chemokine genes) and SIRT6 (degranulation genes) complexes [PMID:37529050]. Across cancers ELK4 directly regulates a broad repertoire of targets including Mcl-1 [PMID:21846680] and KDM5A [PMID:34372882], and its own expression is post-transcriptionally constrained by miR-92b-3p targeting of its 3'UTR [PMID:36556251] and by Staufen-mediated mRNA decay [PMID:32372707]. A recurrent SLC45A3-ELK4 chimeric transcript, generated by trans/cis-splicing rather than rearrangement and androgen-regulated, functions as a nuclear long non-coding chimeric RNA promoting prostate cancer proliferation independently of protein output [PMID:19293179, PMID:28716526].","teleology":[{"year":2009,"claim":"Established that an androgen-regulated SLC45A3-ELK4 chimeric transcript exists in prostate cancer and arises without chromosomal rearrangement, redefining how an ELK4-containing transcript can be deregulated.","evidence":"RT-PCR/qPCR characterization, FISH, and androgen treatment of LNCaP cells","pmids":["19293179"],"confidence":"Medium","gaps":["Did not establish the functional output of the chimeric transcript","Splicing mechanism inferred rather than directly demonstrated"]},{"year":2011,"claim":"Identified ELK4 as a direct transcriptional driver of an anti-apoptotic target, linking ELK4 promoter occupancy to a defined survival phenotype.","evidence":"ETS-site promoter analysis, ELK4 knockdown with Mcl-1 readout, glioblastoma xenograft","pmids":["21846680"],"confidence":"Medium","gaps":["Cofactor requirements at the Mcl-1 promoter not defined","Upstream signal controlling ELK4 at this locus not addressed"]},{"year":2014,"claim":"Distinguished ELK4's SRF-dependent target repertoire (stimulus/infection-response genes) from MKL-driven cytoskeletal programs, defining context-specific genome-wide occupancy.","evidence":"Knockdown plus expression array and ChIP-seq in macrophages","pmids":["24758171"],"confidence":"Medium","gaps":["Did not address non-SRF cofactors","Functional consequences of individual target genes not tested"]},{"year":2015,"claim":"Resolved a direct kinase-substrate link by mapping CDK2 phosphorylation sites controlling ELK4 transcriptional activity, extending ELK4 regulation beyond canonical ERK input.","evidence":"In vitro CDK2 kinase assay, Thr194/Ser387 mutagenesis, transcriptional and transformation assays","pmids":["26028036"],"confidence":"High","gaps":["Relative contribution of CDK2 versus ERK phosphorylation not dissected","Structural basis of activity change unknown"]},{"year":2018,"claim":"Demonstrated cell-autonomous, redundant roles of ELK4 and ELK1 downstream of ERK in T cell development, connecting ELK4-SRF target induction (EGR2) to an organismal immune phenotype.","evidence":"Elk4/Elk1 double-knockout mice, bone marrow chimeras, EGR2 overexpression rescue","pmids":["30068599"],"confidence":"High","gaps":["Direct ELK4 occupancy at thymic targets not mapped","ELK4-specific (non-redundant) functions not isolated"]},{"year":2020,"claim":"Revealed that ELK4 acetylation at K125 licenses a BRD2 partnership for cooperative promoter binding, adding an acetylation-dependent cofactor recruitment layer to ELK4 function.","evidence":"K125 acetylation mapping, Co-IP, ChIP, luciferase, JQ1/U0126 treatment in colorectal cancer","pmids":["32398865"],"confidence":"High","gaps":["Acetyltransferase responsible for K125 not identified","Generality of BRD2 dependence beyond LAMB3 not established"]},{"year":2020,"claim":"Showed ELK4 mRNA is subject to Staufen-mediated decay via a lncRNA, defining a post-transcriptional control point for ELK4 levels.","evidence":"LINC00662 knockdown, mRNA stability and BBB permeability assays","pmids":["32372707"],"confidence":"Low","gaps":["SMD mechanism asserted but not fully reconstituted","Direct LINC00662-ELK4 mRNA interaction not shown"]},{"year":2023,"claim":"Identified SP1/SP3 as SRF-independent ELK4 partners genome-wide and linked MAPK phosphorylation to this interaction, broadening the ELK4 cofactor logic to a non-SRF axis.","evidence":"ChIP-seq, proteomics, Co-IP, serum/MEK-inhibitor phosphorylation assays, LRG1 reporter in colorectal cancer","pmids":["37786278"],"confidence":"High","gaps":["Determinants selecting SP1/SP3 versus SRF binding not defined","Phosphosite mediating SP1/SP3 interaction not mapped"]},{"year":2023,"claim":"Established ELK4 as a platform for hypoxia-driven transcriptional repression via PYCR1 recruitment and SIRT7-mediated H3K18ac deacetylation, linking metabolic NAD+ production to ELK4-targeted chromatin.","evidence":"PYCR1 Tyr135 phosphorylation mapping, Co-IP, ChIP, NAD+/SIRT7 deacetylation assays, xenograft","pmids":["37777542"],"confidence":"High","gaps":["Genome-wide scope of ELK4-PYCR1-SIRT7 repression not defined","How ELK4 switches between activation and repression not resolved"]},{"year":2023,"claim":"Showed ELK4 bifurcates mast cell transcription by partnering with MITF (cytokine genes) versus SIRT6 (degranulation genes), illustrating partner-dependent opposing outputs.","evidence":"Elk4 knockout in BMMCs, Co-IP for MITF and SIRT6, expression and cell-cycle analysis","pmids":["37529050"],"confidence":"Medium","gaps":["Signals controlling partner choice not identified","Direct promoter occupancy at relevant genes not mapped"]},{"year":2021,"claim":"Expanded the ELK4 target repertoire to chromatin and lncRNA regulators (KDM5A, SNHG22), defining downstream epigenetic and stability cascades.","evidence":"ChIP, luciferase, Co-IP, cycloheximide chase in gastric cancer","pmids":["34372882","34663788"],"confidence":"Medium","gaps":["Cofactor requirements at these promoters not defined","Direct versus indirect downstream effects partly inferred"]},{"year":2017,"claim":"Demonstrated the SLC45A3-ELK4 chimera acts as a nuclear long non-coding RNA, regulating proliferation and CDKN1A independently of protein translation.","evidence":"Selective fusion knockdown, translation-incompetent rescue mutants, subcellular fractionation","pmids":["28716526"],"confidence":"Medium","gaps":["RNA effector mechanism/binding partners not identified","Relationship to wild-type ELK4 protein function unclear"]},{"year":2025,"claim":"A series of cancer studies extended ELK4 as a direct transcriptional activator/repressor of diverse targets (FBXO22, CHMP6, MSI2, METTL3, DHFR, HOMER3, PD-L1, FNDC5) across tumor and neuroinflammatory contexts.","evidence":"ChIP/luciferase promoter or enhancer binding with knockdown/rescue phenotypes in multiple disease models","pmids":["37519006","39305302","39969091","40518958","41502523","40205485","39688781","39173777"],"confidence":"Low","gaps":["Most are single-lab, abstract-level mechanistic placements without reconstitution","Cofactor and chromatin context for these targets not defined"]},{"year":null,"claim":"How ELK4 selects among its many cofactors (SRF, SP1/SP3, BRD2, MITF, SIRT6, PYCR1-SIRT7) and switches between activation and repression at a given locus remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of ELK4-cofactor complexes","No integrated map linking phosphorylation/acetylation state to partner choice","Genome-wide repression versus activation determinants undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,3,5,6,8]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,3,5,7]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,5,8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,4,5]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,3,5]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,8]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,4,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,5,9]}],"complexes":[],"partners":["SRF","SP1","SP3","BRD2","PYCR1","SIRT7","MITF","SIRT6"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P28324","full_name":"ETS domain-containing protein Elk-4","aliases":["Serum response factor accessory protein 1","SAP-1","SRF accessory protein 1"],"length_aa":431,"mass_kda":46.9,"function":"Involved in both transcriptional activation and repression. Interaction with SIRT7 leads to recruitment and stabilization of SIRT7 at promoters, followed by deacetylation of histone H3 at 'Lys-18' (H3K18Ac) and subsequent transcription repression. Forms a ternary complex with the serum response factor (SRF). Requires DNA-bound SRF for ternary complex formation and makes extensive DNA contacts to the 5'side of SRF, but does not bind DNA autonomously","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P28324/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ELK4","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ELK4","total_profiled":1310},"omim":[{"mim_id":"620299","title":"MAJOR FACILITATOR SUPERFAMILY DOMAIN-CONTAINING PROTEIN 4A; MFSD4A","url":"https://www.omim.org/entry/620299"},{"mim_id":"611888","title":"ETS2 REPRESSOR FACTOR; ERF","url":"https://www.omim.org/entry/611888"},{"mim_id":"606212","title":"SIRTUIN 7; SIRT7","url":"https://www.omim.org/entry/606212"},{"mim_id":"600247","title":"ELK3, ETS-DOMAIN PROTEIN; ELK3","url":"https://www.omim.org/entry/600247"},{"mim_id":"600246","title":"ELK4, ETS-DOMAIN PROTEIN; ELK4","url":"https://www.omim.org/entry/600246"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ELK4"},"hgnc":{"alias_symbol":["SAP1"],"prev_symbol":[]},"alphafold":{"accession":"P28324","domains":[{"cath_id":"1.10.10.10","chopping":"7-90","consensus_level":"high","plddt":95.9267,"start":7,"end":90}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28324","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28324-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28324-F1-predicted_aligned_error_v6.png","plddt_mean":59.03},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ELK4","jax_strain_url":"https://www.jax.org/strain/search?query=ELK4"},"sequence":{"accession":"P28324","fasta_url":"https://rest.uniprot.org/uniprotkb/P28324.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28324/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28324"}},"corpus_meta":[{"pmid":"19293179","id":"PMC_19293179","title":"SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19293179","citation_count":171,"is_preprint":false},{"pmid":"35526007","id":"PMC_35526007","title":"A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes.","date":"2022","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35526007","citation_count":98,"is_preprint":false},{"pmid":"32398865","id":"PMC_32398865","title":"LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32398865","citation_count":56,"is_preprint":false},{"pmid":"28716526","id":"PMC_28716526","title":"SLC45A3-ELK4 functions as a long non-coding chimeric RNA.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28716526","citation_count":49,"is_preprint":false},{"pmid":"26028036","id":"PMC_26028036","title":"Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/26028036","citation_count":47,"is_preprint":false},{"pmid":"34372882","id":"PMC_34372882","title":"ELK4 promotes the development of gastric cancer by inducing M2 polarization of macrophages through regulation of the KDM5A-PJA2-KSR1 axis.","date":"2021","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34372882","citation_count":43,"is_preprint":false},{"pmid":"34663788","id":"PMC_34663788","title":"ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p/Notch1 axis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34663788","citation_count":43,"is_preprint":false},{"pmid":"22787087","id":"PMC_22787087","title":"SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing.","date":"2012","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/22787087","citation_count":41,"is_preprint":false},{"pmid":"21846680","id":"PMC_21846680","title":"ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1.","date":"2011","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21846680","citation_count":37,"is_preprint":false},{"pmid":"24758171","id":"PMC_24758171","title":"MKL1/2 and ELK4 co-regulate distinct serum response factor (SRF) transcription programs in macrophages.","date":"2014","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24758171","citation_count":32,"is_preprint":false},{"pmid":"32372707","id":"PMC_32372707","title":"TRA2A-induced upregulation of LINC00662 regulates blood-brain barrier permeability by affecting ELK4 mRNA stability in Alzheimer's microenvironment.","date":"2020","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/32372707","citation_count":29,"is_preprint":false},{"pmid":"27498548","id":"PMC_27498548","title":"SIRT7, H3K18ac, and ELK4 Immunohistochemical Expression in Hepatocellular Carcinoma.","date":"2016","source":"Journal of pathology and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27498548","citation_count":28,"is_preprint":false},{"pmid":"37777542","id":"PMC_37777542","title":"IGF1R-phosphorylated PYCR1 facilitates ELK4 transcriptional activity and sustains tumor growth under hypoxia.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37777542","citation_count":25,"is_preprint":false},{"pmid":"37786278","id":"PMC_37786278","title":"ELK4 Promotes Colorectal Cancer Progression by Activating the Neoangiogenic Factor LRG1 in a Noncanonical SP1/3-Dependent Manner.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37786278","citation_count":25,"is_preprint":false},{"pmid":"26938874","id":"PMC_26938874","title":"Role of CTCF in Regulating SLC45A3-ELK4 Chimeric RNA.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26938874","citation_count":22,"is_preprint":false},{"pmid":"8575773","id":"PMC_8575773","title":"Locations of the ets subfamily members net, elk1, and sap1 (ELK3, ELK1, and ELK4) on three homologous regions of the mouse and human genomes.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8575773","citation_count":21,"is_preprint":false},{"pmid":"30068599","id":"PMC_30068599","title":"ERK Signaling Controls Innate-like CD8+ T Cell Differentiation via the ELK4 (SAP-1) and ELK1 Transcription Factors.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30068599","citation_count":20,"is_preprint":false},{"pmid":"22569213","id":"PMC_22569213","title":"Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression.","date":"2012","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22569213","citation_count":16,"is_preprint":false},{"pmid":"37519006","id":"PMC_37519006","title":"ELK4 Promotes Cell Cycle Progression and Stem Cell-like Characteristics in HPV-associated Cervical Cancer by Regulating the FBXO22/PTEN Axis.","date":"2023","source":"Balkan medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/37519006","citation_count":9,"is_preprint":false},{"pmid":"40688093","id":"PMC_40688093","title":"Integrative single-cell and spatial transcriptomics uncover ELK4-mediated mechanisms in NDUFAB1+ tumor cells driving gastric cancer progression, metabolic reprogramming, and immune evasion.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40688093","citation_count":8,"is_preprint":false},{"pmid":"33402177","id":"PMC_33402177","title":"HCG11 up-regulation induced by ELK4 suppressed proliferation in vestibular schwannoma by targeting miR-620/ELK4.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33402177","citation_count":8,"is_preprint":false},{"pmid":"36556251","id":"PMC_36556251","title":"Exosomes from Microvascular Endothelial Cells under Mechanical Unloading Inhibit Osteogenic Differentiation via miR-92b-3p/ELK4 Axis.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36556251","citation_count":7,"is_preprint":false},{"pmid":"37529050","id":"PMC_37529050","title":"ELK4 exerts opposite roles in cytokine/chemokine production and degranulation in activated mast cells.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37529050","citation_count":6,"is_preprint":false},{"pmid":"39688781","id":"PMC_39688781","title":"LncRNA SNHG16 Drives PD-L1-Mediated Immune Escape in Colorectal Cancer through Regulating miR-324-3p/ELK4 Signaling.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39688781","citation_count":5,"is_preprint":false},{"pmid":"39173777","id":"PMC_39173777","title":"ELK4 ameliorates cognitive impairment and neuroinflammation induced by obstructive sleep apnea.","date":"2024","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/39173777","citation_count":4,"is_preprint":false},{"pmid":"36715861","id":"PMC_36715861","title":"Hsa_circ_0119412 Contributes to Development of Retinoblastoma by Targeting miR-186-5p/ELK4 Axis.","date":"2023","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/36715861","citation_count":3,"is_preprint":false},{"pmid":"39305302","id":"PMC_39305302","title":"ELK4 targets CHMP6 to inhibit ferroptosis and enhance malignant properties of skin cutaneous melanoma cells.","date":"2024","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/39305302","citation_count":2,"is_preprint":false},{"pmid":"40205485","id":"PMC_40205485","title":"ELK4 induced upregulation of HOMER3 promotes the proliferation and metastasis in glioma via Wnt/β-catenin/EMT signaling pathway.","date":"2025","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/40205485","citation_count":2,"is_preprint":false},{"pmid":"39969091","id":"PMC_39969091","title":"ELK4 transcription promotes MSI2-mediated progression of non-small cell lung cancer through the TGF-β/SMAD3 pathway.","date":"2025","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39969091","citation_count":2,"is_preprint":false},{"pmid":"40663811","id":"PMC_40663811","title":"The role of ELK4 up-regulation in macrophage polarization and its mechanism in connective tissue disease-associated interstitial lung disease.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40663811","citation_count":1,"is_preprint":false},{"pmid":"38566572","id":"PMC_38566572","title":"miR-129-5p inhibits anchorage-independent growth through silencing of ACTN1 and the ELK4/c-FOS axis in HPV-transformed keratinocytes.","date":"2024","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/38566572","citation_count":1,"is_preprint":false},{"pmid":"40518958","id":"PMC_40518958","title":"Identification of the Pro-Tumorigenic Role of the ELK4-METTL3-CEMIP Axis in Colorectal Carcinoma: Promotion of Cancer Cell Stemness and Malignant Phenotypes.","date":"2025","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/40518958","citation_count":1,"is_preprint":false},{"pmid":"38923578","id":"PMC_38923578","title":"CircNUP98 promotes the malignant behavior of glioma cells through the miR-520f-3p/ELK4 axis.","date":"2024","source":"International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/38923578","citation_count":0,"is_preprint":false},{"pmid":"41502523","id":"PMC_41502523","title":"ELK4 Promotes Vasculogenic Mimicry in Oral Squamous Cell Carcinoma via Driving DHFR Transcriptional Activation.","date":"2025","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/41502523","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":19986,"output_tokens":5672,"usd":0.072519,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14052,"output_tokens":4403,"usd":0.090167,"stage2_stop_reason":"end_turn"},"total_usd":0.162686,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2015,\n      \"finding\": \"CDK2 directly phosphorylates ELK4 at Thr194 and Ser387, and this phosphorylation regulates ELK4 transcriptional activity to control c-fos expression downstream of EGF signaling.\",\n      \"method\": \"In vitro kinase assay (CDK2 phosphorylates ELK4), site-directed mutagenesis at Thr194 and Ser387, transcriptional activity assays, knockdown of CDK2/ELK4 with phenotypic readout (EGF-induced cell transformation)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation assay with specific residue identification, mutagenesis, and functional transcriptional readout; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26028036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ELK4 is acetylated at K125; this acetylation enhances its interaction with BRD2, and the ELK4-BRD2 complex cooperatively binds ETS motifs in the LAMB3 promoter to drive LAMB3 transcription in colorectal cancer. The BET inhibitor JQ1 disrupts the ELK4-BRD2 interaction, reducing BRD2 occupancy at the LAMB3 promoter.\",\n      \"method\": \"ChIP, Co-IP, luciferase reporter assay, acetylation mapping at K125, JQ1/U0126 treatment with mRNA level readout\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — acetylation site identified, complex validated by Co-IP, promoter binding confirmed by ChIP, functional disruption by inhibitor; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32398865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ELK4 co-regulates a distinct set of SRF-dependent genes related to external stimulus/infection responses in macrophages (separate from MKL1/2-regulated cytoskeletal genes), acting directly in cis at target gene promoters.\",\n      \"method\": \"Knockdown combined with gene expression array; ChIP-seq for genome-wide occupancy mapping\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq genome-wide occupancy plus knockdown/expression array; single lab, two orthogonal methods\",\n      \"pmids\": [\"24758171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ELK4 binds to a functional ETS binding site in the Mcl-1 promoter and is a critical transcriptional regulator of Mcl-1 expression in glioma; ELK4 downregulation reduces Mcl-1 levels, increases apoptosis sensitivity, and reduces tumor formation in vivo. A SNP that ablates ELK4 binding correlates with lower Mcl-1 levels.\",\n      \"method\": \"Promoter analysis, ETS binding site identification, ELK4 knockdown with Mcl-1 mRNA/protein readout, glioblastoma xenograft model\",\n      \"journal\": \"Neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter binding assay, knockdown with defined molecular and in vivo phenotype; single lab, multiple methods\",\n      \"pmids\": [\"21846680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PYCR1 is phosphorylated by nuclear IGF1R at Tyrosine 135 under hypoxia, and this phosphorylation promotes PYCR1 binding to ELK4 and recruitment of PYCR1 to ELK4-targeted gene promoters. PYCR1 enzymatic activity produces NAD+ that stimulates SIRT7 deacetylation of H3K18ac, cooperating with the ELK4-SIRT7 complex to mediate transcriptional repression.\",\n      \"method\": \"Phosphorylation mapping (Tyr135), co-IP for PYCR1-ELK4 interaction, ChIP for promoter recruitment, enzymatic activity assay for PYCR1-derived NAD+, SIRT7 deacetylation assay, in vivo xenograft\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — phosphorylation site mapped, protein-protein interaction validated by Co-IP, ChIP for promoter recruitment, enzymatic activity linked to deacetylation; single lab with multiple rigorous orthogonal methods\",\n      \"pmids\": [\"37777542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ELK4 cooperates with SP1 and SP3 (rather than SRF) as functional partners at the genome-wide level in colorectal cancer; MAPK-induced phosphorylation of ELK4 facilitates its interaction with SP1/SP3. The ELK4-SP1/SP3 complex directly activates transcription of LRG1, a neoangiogenic factor.\",\n      \"method\": \"Integrated genomics and proteomics, ChIP-seq for genome-wide occupancy, Co-IP for ELK4-SP1/SP3 interaction, phosphorylation assay (serum-induced MAPK), luciferase reporter for LRG1 promoter, combination treatment with MEK inhibitor and mithramycin A\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP-seq, proteomics, Co-IP, phosphorylation, functional reporter assay, in vivo experiments; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"37786278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ELK4 transcriptionally activates KDM5A by directly binding its promoter; KDM5A then removes H3K4me3 from the PJA2 promoter to repress PJA2 expression, leading to reduced ubiquitination-mediated degradation of KSR1. This ELK4-KDM5A-PJA2-KSR1 axis promotes M2 macrophage polarization and gastric cancer progression.\",\n      \"method\": \"Dual luciferase reporter, ChIP, Co-IP, cycloheximide chase (KSR1 protein stability), gain/loss-of-function, xenograft model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase confirm direct promoter binding, Co-IP, protein stability assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"34372882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ELK4 transcription factor binds to the SNHG22 promoter and promotes SNHG22 lncRNA expression in gastric cancer cells.\",\n      \"method\": \"ChIP assay, luciferase reporter assay\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and luciferase confirm direct promoter binding; single lab, limited to promoter binding assay\",\n      \"pmids\": [\"34663788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ELK4 (SAP-1) and ELK1 act cell-autonomously in the thymus downstream of ERK signaling to control the generation of innate-like αβ CD8+ T cells; mice lacking both ELK4 and ELK1 develop increased numbers of innate-like CD8+ T cells associated with reduced TCR-mediated activation of ELK4-SRF target genes (e.g., EGR2), and overexpression of EGR2 partially suppresses this phenotype.\",\n      \"method\": \"Elk4 and Elk1 knockout mice (genetic epistasis), thymic cell-autonomy demonstrated by bone marrow chimeras, target gene expression analysis, EGR2 overexpression rescue\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis using double KO mice, cell-autonomous rescue experiments, target gene analysis; single lab but multiple rigorous genetic methods\",\n      \"pmids\": [\"30068599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The SLC45A3-ELK4 chimeric transcript is androgen-regulated (not wild-type ELK4), and is generated through a mechanism other than chromosomal rearrangement, most likely trans-splicing, in prostate cancer. SLC45A3 exon 1 is fused to ELK4 exon 2 in the major variant.\",\n      \"method\": \"RT-PCR characterization, quantitative PCR on DNA and RNA, androgen (R1881) treatment of LNCaP cells, FISH for chromosomal rearrangement\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (RT-PCR, qPCR, FISH, androgen treatment) in single study; cis-splicing mechanism later supported by independent lab (PMID 22787087)\",\n      \"pmids\": [\"19293179\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The SLC45A3-ELK4 fusion transcript functions as a long non-coding chimeric RNA (lnccRNA) to promote prostate cancer cell proliferation; the fusion RNA encodes the same protein as ELK4 but is present at <1% of wild-type ELK4 levels. A translation-incompetent mutant of the fusion RNA retains the ability to regulate cell proliferation and suppress CDKN1A, and the fusion RNA is enriched in the nuclear fraction.\",\n      \"method\": \"RNA silencing (selective knockdown of fusion vs. wild-type ELK4), rescue with translation-competent and translation-incompetent mutants, subcellular fractionation, cell proliferation assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — selective silencing, multiple rescue constructs, fractionation; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"28716526\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ELK4 binds to the FBXO22 promoter and transcriptionally inhibits FBXO22 expression, leading to reduced PTEN levels and promotion of cell cycle progression and stem cell-like characteristics in HPV+ cervical cancer cells.\",\n      \"method\": \"ChIP-qPCR, luciferase reporter assay, ELK4 knockdown with cell cycle and stemness phenotype readouts\",\n      \"journal\": \"Balkan medical journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and luciferase confirm binding, but single lab, limited mechanistic follow-up for PTEN regulation\",\n      \"pmids\": [\"37519006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ELK4 positively modulates cytokine/chemokine (Hdc, Ccl3, Ccl4) transcription by interacting with MITF, while negatively regulating degranulation-related gene transcription by complexing with SIRT6 in mast cells. ELK4 knockout suppresses mast cell proliferation and impedes cell cycle progression.\",\n      \"method\": \"Elk4 knockout in BMMCs, gene expression analysis, Co-IP for ELK4-MITF and ELK4-SIRT6 interactions, transcriptional activity assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined cellular phenotypes, Co-IP for two distinct complexes; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37529050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ELK4 directly binds to the CHMP6 promoter to transcriptionally activate CHMP6 expression, thereby inhibiting ferroptosis (reducing ROS and Fe2+ levels, increasing GPX4 and xCT, decreasing ACSL4) and promoting proliferation, invasion, and migration in skin cutaneous melanoma cells.\",\n      \"method\": \"ChIP assay for ELK4 binding to CHMP6 promoter, ELK4/CHMP6 overexpression and knockdown with ROS/Fe2+ measurements and ferroptosis marker protein levels\",\n      \"journal\": \"Archives of dermatological research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP confirms promoter binding, functional rescue data; single lab, limited mechanistic depth\",\n      \"pmids\": [\"39305302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ELK4 acts as a transcription factor that directly binds the MSI2 promoter to promote MSI2 transcription in NSCLC, and MSI2 in turn promotes NSCLC progression through the TGF-β/SMAD3 pathway.\",\n      \"method\": \"ChIP assay, dual luciferase reporter assay, ELK4/MSI2 knockdown/overexpression with proliferation/invasion assays, xenograft model\",\n      \"journal\": \"The Kaohsiung journal of medical sciences\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and luciferase confirm direct binding; single lab, pathway placement by knockdown without reconstitution\",\n      \"pmids\": [\"39969091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ELK4 promotes FNDC5 transcription by binding to the FNDC5 promoter; ELK4 overexpression in microglia suppresses neuroinflammation and cognitive dysfunction in an OSA mouse model through this FNDC5-dependent mechanism.\",\n      \"method\": \"Promoter binding assay (ChIP implied), ELK4 overexpression/FNDC5 knockdown rescue experiments in BV2 cells and OSA mouse model\",\n      \"journal\": \"Brain research bulletin\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — promoter binding assay and genetic rescue establish pathway placement; single lab, abstract-level detail only\",\n      \"pmids\": [\"39173777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ELK4 transcriptionally upregulates METTL3 by direct promoter binding; METTL3 then stabilizes CEMIP mRNA, and the resulting ELK4-METTL3-CEMIP axis promotes stemness and malignant phenotypes in colorectal cancer.\",\n      \"method\": \"ChIP assay for ELK4 binding to METTL3 promoter, luciferase reporter, RIP and mRNA stability assay for METTL3-CEMIP, ELK4 knockdown xenograft\",\n      \"journal\": \"Journal of gastroenterology and hepatology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and luciferase confirm promoter binding; single lab, abstract-level detail for downstream axis\",\n      \"pmids\": [\"40518958\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ELK4 directly binds to DHFR enhancer regions to activate DHFR transcription, promoting vasculogenic mimicry and invasion in oral squamous cell carcinoma; DHFR overexpression rescues VM and invasion impairment caused by ELK4 knockdown.\",\n      \"method\": \"ChIP-qPCR for ELK4 binding to DHFR enhancer, ELK4 knockdown and DHFR rescue with Matrigel tube formation and Transwell invasion assays\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP-qPCR confirms enhancer binding, functional rescue confirms pathway; single lab, limited mechanistic depth\",\n      \"pmids\": [\"41502523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ELK4 binds to the HOMER3 promoter to promote its transcription in glioma; ELK4-driven HOMER3 expression activates the Wnt/β-catenin/EMT signaling pathway, promoting glioma cell proliferation and metastasis.\",\n      \"method\": \"ChIP for ELK4-HOMER3 promoter binding, HOMER3 silencing with proliferation/metastasis assays in vitro and in vivo, EMT marker expression\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP confirms promoter binding, functional data; single lab, abstract-level mechanistic detail\",\n      \"pmids\": [\"40205485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LINC00662 mediates degradation of ELK4 mRNA through the Staufen-mediated mRNA decay (SMD) pathway in microvascular endothelial cells; reduced ELK4 increases BBB permeability by increasing tight junction-related protein expression.\",\n      \"method\": \"RNA knockdown, mRNA stability assay, BBB permeability assay, tight junction protein expression\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional pathway established by knockdown; single lab, SMD mechanism asserted but not fully reconstituted in abstract\",\n      \"pmids\": [\"32372707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ELK4 transcription factor promotes SNHG22 lncRNA expression in gastric cancer; this was confirmed by ChIP and the 3' UTR of ELK4 mRNA is targeted by miR-92b-3p delivered by exosomes from mechanically unloaded MVECs, leading to suppressed osteogenic differentiation.\",\n      \"method\": \"ChIP (ELK4-SNHG22 promoter); luciferase reporter for miR-92b-3p targeting ELK4 3'UTR; siRNA-ELK4 rescue experiments\",\n      \"journal\": \"Journal of personalized medicine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — luciferase confirms 3'UTR targeting, siRNA rescue; single lab, functional context is indirect (exosome-mediated)\",\n      \"pmids\": [\"36556251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ELK4 directly activates PD-L1 transcription in colorectal cancer; the lncRNA SNHG16 acts as a competitive endogenous RNA to sponge miR-324-3p, which normally suppresses ELK4 expression, thereby increasing ELK4-driven PD-L1 transcription and promoting immune escape.\",\n      \"method\": \"Dual luciferase assay, RIP, ChIP, knockdown/overexpression with immune escape functional assays (LDH cytotoxicity, flow cytometry)\",\n      \"journal\": \"Biochemical genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and luciferase confirm ELK4-PD-L1 promoter binding; single lab, pathway placement by knockdown\",\n      \"pmids\": [\"39688781\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ELK4 is an ETS-family transcription factor (TCF subfamily) that acts primarily as a downstream effector of MAPK/ERK signaling: ERK-mediated phosphorylation (and CDK2 phosphorylation at Thr194/Ser387) enhances ELK4 transcriptional activity; ELK4 can form complexes with SRF (activating immediate-early genes such as c-fos and EGR family members in T cell development and stimulus responses), with BRD2 (dependent on ELK4 acetylation at K125, driving LAMB3 transcription in CRC), with SP1/SP3 in an SRF-independent manner (driving LRG1 in CRC), with MITF or SIRT6 in mast cells, and with PYCR1-SIRT7 to mediate H3K18ac deacetylation and transcriptional repression under hypoxia; ELK4 directly activates or represses multiple target gene promoters (Mcl-1, KDM5A, SNHG22, PD-L1, MSI2, METTL3, DHFR, HOMER3, CHMP6, FBXO22, FNDC5) and its own expression is post-transcriptionally regulated by miR-92b-3p (3'UTR targeting) and lncRNA-mediated mRNA decay.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ELK4 is a sequence-specific ETS-family transcription factor that functions as a downstream nuclear effector of MAPK/ERK signaling, binding ETS motifs at target promoters and enhancers to activate or repress transcription [#5, #3]. Its activity is gated by post-translational modification: CDK2 directly phosphorylates ELK4 at Thr194 and Ser387 to control c-fos expression downstream of EGF signaling [#0], and MAPK-induced phosphorylation promotes its assembly with partner factors [#5]. ELK4 operates through a versatile set of cofactor complexes whose composition dictates target specificity—it co-regulates SRF-dependent stimulus/infection-response genes [#2], cooperates with SP1/SP3 in an SRF-independent manner to activate the neoangiogenic factor LRG1 [#5], and depends on K125 acetylation to recruit BRD2 to the LAMB3 promoter [#1]. Beyond classical activation, ELK4 mediates transcriptional repression: under hypoxia, phosphorylated PYCR1 binds ELK4 and is recruited to ELK4-target promoters, where PYCR1-derived NAD+ stimulates SIRT7-dependent H3K18ac deacetylation [#4]. In immune and developmental contexts, ELK4 acts cell-autonomously in the thymus together with ELK1 to drive ERK-dependent SRF target genes such as EGR2 and restrain innate-like CD8+ T cell generation [#8], and in mast cells it partitions between MITF (cytokine/chemokine genes) and SIRT6 (degranulation genes) complexes [#12]. Across cancers ELK4 directly regulates a broad repertoire of targets including Mcl-1 [#3] and KDM5A [#6], and its own expression is post-transcriptionally constrained by miR-92b-3p targeting of its 3'UTR [#20] and by Staufen-mediated mRNA decay [#19]. A recurrent SLC45A3-ELK4 chimeric transcript, generated by trans/cis-splicing rather than rearrangement and androgen-regulated, functions as a nuclear long non-coding chimeric RNA promoting prostate cancer proliferation independently of protein output [#9, #10].\",\n  \"teleology\": [\n    {\n      \"year\": 2009,\n      \"claim\": \"Established that an androgen-regulated SLC45A3-ELK4 chimeric transcript exists in prostate cancer and arises without chromosomal rearrangement, redefining how an ELK4-containing transcript can be deregulated.\",\n      \"evidence\": \"RT-PCR/qPCR characterization, FISH, and androgen treatment of LNCaP cells\",\n      \"pmids\": [\"19293179\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not establish the functional output of the chimeric transcript\", \"Splicing mechanism inferred rather than directly demonstrated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified ELK4 as a direct transcriptional driver of an anti-apoptotic target, linking ELK4 promoter occupancy to a defined survival phenotype.\",\n      \"evidence\": \"ETS-site promoter analysis, ELK4 knockdown with Mcl-1 readout, glioblastoma xenograft\",\n      \"pmids\": [\"21846680\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cofactor requirements at the Mcl-1 promoter not defined\", \"Upstream signal controlling ELK4 at this locus not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Distinguished ELK4's SRF-dependent target repertoire (stimulus/infection-response genes) from MKL-driven cytoskeletal programs, defining context-specific genome-wide occupancy.\",\n      \"evidence\": \"Knockdown plus expression array and ChIP-seq in macrophages\",\n      \"pmids\": [\"24758171\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not address non-SRF cofactors\", \"Functional consequences of individual target genes not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved a direct kinase-substrate link by mapping CDK2 phosphorylation sites controlling ELK4 transcriptional activity, extending ELK4 regulation beyond canonical ERK input.\",\n      \"evidence\": \"In vitro CDK2 kinase assay, Thr194/Ser387 mutagenesis, transcriptional and transformation assays\",\n      \"pmids\": [\"26028036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CDK2 versus ERK phosphorylation not dissected\", \"Structural basis of activity change unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated cell-autonomous, redundant roles of ELK4 and ELK1 downstream of ERK in T cell development, connecting ELK4-SRF target induction (EGR2) to an organismal immune phenotype.\",\n      \"evidence\": \"Elk4/Elk1 double-knockout mice, bone marrow chimeras, EGR2 overexpression rescue\",\n      \"pmids\": [\"30068599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ELK4 occupancy at thymic targets not mapped\", \"ELK4-specific (non-redundant) functions not isolated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed that ELK4 acetylation at K125 licenses a BRD2 partnership for cooperative promoter binding, adding an acetylation-dependent cofactor recruitment layer to ELK4 function.\",\n      \"evidence\": \"K125 acetylation mapping, Co-IP, ChIP, luciferase, JQ1/U0126 treatment in colorectal cancer\",\n      \"pmids\": [\"32398865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Acetyltransferase responsible for K125 not identified\", \"Generality of BRD2 dependence beyond LAMB3 not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed ELK4 mRNA is subject to Staufen-mediated decay via a lncRNA, defining a post-transcriptional control point for ELK4 levels.\",\n      \"evidence\": \"LINC00662 knockdown, mRNA stability and BBB permeability assays\",\n      \"pmids\": [\"32372707\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"SMD mechanism asserted but not fully reconstituted\", \"Direct LINC00662-ELK4 mRNA interaction not shown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified SP1/SP3 as SRF-independent ELK4 partners genome-wide and linked MAPK phosphorylation to this interaction, broadening the ELK4 cofactor logic to a non-SRF axis.\",\n      \"evidence\": \"ChIP-seq, proteomics, Co-IP, serum/MEK-inhibitor phosphorylation assays, LRG1 reporter in colorectal cancer\",\n      \"pmids\": [\"37786278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants selecting SP1/SP3 versus SRF binding not defined\", \"Phosphosite mediating SP1/SP3 interaction not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established ELK4 as a platform for hypoxia-driven transcriptional repression via PYCR1 recruitment and SIRT7-mediated H3K18ac deacetylation, linking metabolic NAD+ production to ELK4-targeted chromatin.\",\n      \"evidence\": \"PYCR1 Tyr135 phosphorylation mapping, Co-IP, ChIP, NAD+/SIRT7 deacetylation assays, xenograft\",\n      \"pmids\": [\"37777542\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide scope of ELK4-PYCR1-SIRT7 repression not defined\", \"How ELK4 switches between activation and repression not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ELK4 bifurcates mast cell transcription by partnering with MITF (cytokine genes) versus SIRT6 (degranulation genes), illustrating partner-dependent opposing outputs.\",\n      \"evidence\": \"Elk4 knockout in BMMCs, Co-IP for MITF and SIRT6, expression and cell-cycle analysis\",\n      \"pmids\": [\"37529050\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signals controlling partner choice not identified\", \"Direct promoter occupancy at relevant genes not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Expanded the ELK4 target repertoire to chromatin and lncRNA regulators (KDM5A, SNHG22), defining downstream epigenetic and stability cascades.\",\n      \"evidence\": \"ChIP, luciferase, Co-IP, cycloheximide chase in gastric cancer\",\n      \"pmids\": [\"34372882\", \"34663788\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cofactor requirements at these promoters not defined\", \"Direct versus indirect downstream effects partly inferred\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated the SLC45A3-ELK4 chimera acts as a nuclear long non-coding RNA, regulating proliferation and CDKN1A independently of protein translation.\",\n      \"evidence\": \"Selective fusion knockdown, translation-incompetent rescue mutants, subcellular fractionation\",\n      \"pmids\": [\"28716526\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RNA effector mechanism/binding partners not identified\", \"Relationship to wild-type ELK4 protein function unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A series of cancer studies extended ELK4 as a direct transcriptional activator/repressor of diverse targets (FBXO22, CHMP6, MSI2, METTL3, DHFR, HOMER3, PD-L1, FNDC5) across tumor and neuroinflammatory contexts.\",\n      \"evidence\": \"ChIP/luciferase promoter or enhancer binding with knockdown/rescue phenotypes in multiple disease models\",\n      \"pmids\": [\"37519006\", \"39305302\", \"39969091\", \"40518958\", \"41502523\", \"40205485\", \"39688781\", \"39173777\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Most are single-lab, abstract-level mechanistic placements without reconstitution\", \"Cofactor and chromatin context for these targets not defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ELK4 selects among its many cofactors (SRF, SP1/SP3, BRD2, MITF, SIRT6, PYCR1-SIRT7) and switches between activation and repression at a given locus remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of ELK4-cofactor complexes\", \"No integrated map linking phosphorylation/acetylation state to partner choice\", \"Genome-wide repression versus activation determinants undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 3, 5, 6, 8]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 3, 5, 7]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 5, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 4, 5]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 3, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 8]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 4, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 5, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SRF\", \"SP1\", \"SP3\", \"BRD2\", \"PYCR1\", \"SIRT7\", \"MITF\", \"SIRT6\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}